Niveau de difficulté : * * Mots clés : Non-infériorité - Per protocol (PP) - ITT - Bornes Contexte Les essais de non-infériorité sont souvent mal connus des cliniciens. En effet, ils [...]
Réf : Convergences.online/Hemato ; 2 (7) : V63 EORTC Quality of Life Group. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia. [...]
Réf : Convergences.online/Hemato ; 2 (7) : V62 Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, [...]
Réf : Convergences.online/Hemato ; 2 (7) : V60 Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, Martinez-Calle N, Parry-Jones [...]
Réf : Convergences.online/Hemato ; 2 (7) : V59 Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Rigolin GM, Del Giudice I, Bardi [...]
Réf : Convergences.online/Hemato ; 2 (7) : V58 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg [...]
Réf : Convergences.online/Hemato ; 2 (7) : V57 The CLL12 trial: ibrutinib vs. placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, [...]
Réf. : Convergences.online/Hemato ; 2 (7) : R53 Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Al-Sawaf O, Zhang C, Lu T, Liao MZ, [...]
Réf. : Convergences.online/Hemato ; 2 (7) : R52 Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase [...]
Réf. Convergences.online/Hemato ; 2(4) : U11 Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Byrd JC, Hillmen P, Ghia P, Kater AP, [...]
